News & Events
Inmagene has a robust and growing pipeline, focused on treating immunological diseases.
Inmagene is enrolling patients for a phase 1 clinical study of IMG-007.
Inmagene has formed strategic partnerships with Affibody AB and HUTCHMED (Nasdaq/AIM: HCM) to develop highly innovative drug candidates.
Inmagene has several assets with strong differentiations available for partnering.
News and Events
View all news